Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Reexamination Certificate
2007-10-12
2010-06-29
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
C530S390500, C530S414000, C530S417000
Reexamination Certificate
active
07744890
ABSTRACT:
Methods for reducing the opalescent appearance of a protein preparation by modifying the ionic strength of the preparation, as well as compositions, e.g., pharmaceutical compositions, of concentrated protein with decreased opalescence are disclosed. Purification methods which monitor and/or reduce the salt concentrations at selected steps are also disclosed.
REFERENCES:
patent: 4396608 (1983-08-01), Tenold
patent: 4399216 (1983-08-01), Axel et al.
patent: 4510245 (1985-04-01), Cousens et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4704362 (1987-11-01), Itakura et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4849508 (1989-07-01), Magnin et al.
patent: 4968615 (1990-11-01), Koszinowski et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5179017 (1993-01-01), Axel et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5304489 (1994-04-01), Rosen
patent: 5428130 (1995-06-01), Capon et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5516964 (1996-05-01), Umansky et al.
patent: 5549892 (1996-08-01), Friedman et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5786160 (1998-07-01), Anderson et al.
patent: 5849992 (1998-12-01), Meade et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6193980 (2001-02-01), Efstathiou et al.
patent: 6238664 (2001-05-01), Hellerbrand et al.
patent: 6281336 (2001-08-01), Laursen et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6939545 (2005-09-01), Jacobs et al.
patent: 2002/0157125 (2002-10-01), Lee et al.
patent: 2003/0018004 (2003-01-01), Kingsman et al.
patent: 2003/0070185 (2003-04-01), Jakobovits et al.
patent: 2003/0108549 (2003-06-01), Carter et al.
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: 2004/0082762 (2004-04-01), Basi et al.
patent: 2004/0082764 (2004-04-01), Kunz et al.
patent: 2004/0087777 (2004-05-01), Basi et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2004/0197324 (2004-10-01), Liu et al.
patent: 2005/0032216 (2005-02-01), Kingsman et al.
patent: 2005/0042220 (2005-02-01), Li et al.
patent: 2005/0100958 (2005-05-01), Stern et al.
patent: 2005/0118651 (2005-06-01), Basi et al.
patent: 2005/0136049 (2005-06-01), Ledbetter et al.
patent: 2005/0158760 (2005-07-01), Jacobs et al.
patent: 2005/0249725 (2005-11-01), Schenk et al.
patent: 2006/0063228 (2006-03-01), Kasaian et al.
patent: 2006/0073148 (2006-04-01), Tchistiakova et al.
patent: 2006/0088522 (2006-04-01), Boghaert et al.
patent: 171496 (1986-02-01), None
patent: 0173494 (1986-03-01), None
patent: 0239400 (1987-09-01), None
patent: 417014 (1991-03-01), None
patent: 417563 (1991-03-01), None
patent: 2177096 (1987-01-01), None
patent: WO-8907947 (1989-09-01), None
patent: WO-90/02809 (1990-03-01), None
patent: WO-9111172 (1991-08-01), None
patent: WO-91/17271 (1991-11-01), None
patent: WO-9201047 (1992-01-01), None
patent: WO-9206193 (1992-04-01), None
patent: WO-92/09690 (1992-06-01), None
patent: WO-92/15679 (1992-09-01), None
patent: WO-92/18619 (1992-10-01), None
patent: WO-92/20791 (1992-11-01), None
patent: WO-93/01288 (1993-01-01), None
patent: WO-9402518 (1994-02-01), None
patent: WO-96/33735 (1996-10-01), None
patent: WO-96/34096 (1996-10-01), None
patent: WO-98/52976 (1998-11-01), None
patent: WO-9855148 (1998-12-01), None
patent: WO-0029428 (2000-05-01), None
patent: WO-0034317 (2000-06-01), None
patent: WO-0136486 (2001-05-01), None
patent: WO-0162801 (2001-08-01), None
patent: WO-0246237 (2002-06-01), None
patent: WO-02088306 (2002-11-01), None
patent: WO-02088307 (2002-11-01), None
patent: WO-03077858 (2003-09-01), None
patent: WO-2004/091658 (2004-10-01), None
patent: WO-2004108895 (2004-12-01), None
patent: WO-2008/045563 (2008-04-01), None
International Search Report to PCT/US2007/021904 dated Apr. 4, 2008.
Written Opinion of the International Searching Authority to PCT/US2007/021904 dated .
Bajaj Harminder et al, “Protein structural conformation and not second viral coefficient relates to long-term irreversible aggregation of monoclonal antibody and ovalbumin in solution.”,Pharmaceutical Research, Jun. 2006, pp. 1382-1394, vol. 23, No. 6.
Sisti A M et al, “Preparation of lyophilized and liquid intravenous immunoglobulin G: Development and scale-up”,Vox Sanguinis, May 2001, pp. 216-224, vol. 80, No. 4.
A. Wilcox, J. Guo, T. Spitznagel, R. Krishnamurthy, “Opalescence of a Monoclonal Antibody and its Dependence on Ionic Strength and Temperature”, 2005 AAPS Annual Meeting and Exposition, Nov. 2005.
Chi Eva Y et al, “Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation”,Pharmaceutical Research(Dordrecht), Sep. 2003, pp. 1325-1336, vol. 20, No. 9.
Harris Reed J et al, “Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies”,Drug Development Research, Mar. 2004, pp. 137-154, vol. 61, No. 3.
Ahrer et al, “Thermodynamic stability and formation of aggregates of human immunoglobulin G characterised by differential scanning calorimetry and dynamic light scattering”,Journal of Biochemical and Biophysical Methods, Mar. 2006, pp. 73-86, vol. 66, Nos. 1-3.
Liu J et al, Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution,Journal of Pharmaceutical Sciences, Sep. 2005, pp. 1928-1940, vol. 94, p. 9.
Fatouros Angelica et al, “Recombinant factor VIII SQ: Influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution”,International Journal of Pharmaceutics, 1997, pp. 121-131, vol. 155, No. 1.
Wang Wei, “Instability, stabilization, and formulation of liquid protein pharmaceuticals”,International Journal of Pharmaceutics, Aug. 1999, pp. 129-188, vol. 185, No. 2.
Wang W, “Protein aggregation and its inhibition in biopharmaceutics”,International Journal of Pharmaceutics, Jan. 2005, pp. 1-30, vol. 289, Nos. 1-2.
Izutsu Ken-Ichi, “Stabilization of therapeutic proteins by chemical and physical methods”,Methods in Molecular Biology, 2005, pp. 287-292, vol. 308.
Schreiber Gideon, “Kinetic studies of protein-protein interactions”,Current Opinion in Structural Biology, Feb. 2002, pp. 41-47, vol. 12, No. 1.
Anonymous, “Workshop on Protein Aggregation—Summary of Responses to Questions for Breakout Sessions”, Internet Article retrieved from the Internet: URL:http://www.aapspharmaceutica.com/inside/Focus—Groups/ProteinAgg/imagespdfs/ProteinWrkshpBOInfo2006.pdf, Sep. 2006.
Brekke, O.H. and Sandlie, I., “Therapeutic antibodies for human diseases at the dawn of the twenty-first century”, Nat. Rev. Drug Discov., 2003, vol. 2, pp. 52-62.
Schellekens, H., “Bioequivalence and the immunogenicity of biopharmaceuticals”, Nat. Rev. Drug Discov., 2002, vol. 1, pp. 457-462.
Pinckard et al., “Factors influencing the immune response: Effects of the physical state of the antigen and of lymphoreticular cell proliferation on the response to intraperitoneal injection of bovine serum albumin in rabbits”, Clin Exp. Immunol., 1967, vol. 2, pp. 331-340.
Robbins et al., “Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients”, Diabetes, 1987, vol. 36, pp. 838-845.
Cleland et al., “The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation”, Crit. Rev. Therapeutic Drug Carrier Systems, 1993, vol. 10, p. 307-377.
Miro, M. et al., Analytica
Luisi Donna L.
Nichols Pilarin Elizabeth
Ng Mabel
Saunders David A
Wyeth LLC
LandOfFree
Methods and compositions with reduced opalescence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions with reduced opalescence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions with reduced opalescence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204972